Maria Leon-Camarena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Leon-Camarena has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dragan Vujovic
Icahn Sch Med Mt Sinai, Dept Otolaryngol Head & Neck Surg, 1468 Madison Ave, New York, NY USA
1 shared publication - Kevin Innella
Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA
1 shared publication - Maureen Aliru
Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
1 shared publication - Mihailo Miljanic
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication - Puneeth Iyengar
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Ritsuko Komaki
Department of Radiation Oncology, Emeritus of The University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, Houston, TX, United States
1 shared publication
Latest Publications
- Open Access
The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field
In this commentary, we describe the potential of highly ablative doses utilizing Stereotactic Body Radiation Therapy (SBRT) in single or few fractions to enhance immune-responsiveness, how timing of this approach in combination with immune-checkpoint inhibitors may augment treatment-effect, and whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) is an avenue for future advancement in the continued endeavor to foster a systemic effect of therapy beyond the radiation treatment field. The ablative potential of SBRT may support an increase in tumor-antigen presentation, enhancement of immune-stimulatory components, and an improvement in tumor-microenvironment immune cell infiltration. Furthermore, the latest advancement of ablative radiation delivery is PULSAR-based therapy, whereby ablative doses are delivered in pulses of treatment that may be several weeks apart, combined with adaptive treatment to tumor changes across time. The benefits of this novel approach include the ability to optimize direct tumor control by assessment of tumor size and location via dedicated imaging acquired prior to each delivered pulse, and further potentiation of immune recognition through combination with concurrent immune-checkpoint blockade.
Open AccessThe Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field
In this commentary, we describe the potential of highly ablative doses utilizing Stereotactic Body Radiation Therapy (SBRT) in single or few fractions to enhance immune-responsiveness, how timing of this approach in combination with immune-checkpoint inhibitors may augment treatment-effect, and whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) is an avenue for future advancement in the continued endeavor to foster a systemic effect of therapy beyond the radiation treatment field. The ablative potential of SBRT may support an increase in tumor-antigen presentation, enhancement of immune-stimulatory components, and an improvement in tumor-microenvironment immune cell infiltration. Furthermore, the latest advancement of ablative radiation delivery is PULSAR-based therapy, whereby ablative doses are delivered in pulses of treatment that may be several weeks apart, combined with adaptive treatment to tumor changes across time. The benefits of this novel approach include the ability to optimize direct tumor control by assessment of tumor size and location via dedicated imaging acquired prior to each delivered pulse, and further potentiation of immune recognition through combination with concurrent immune-checkpoint blockade.